Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that cubosomes combined with dissolving microneedles enhanced transdermal penetration and hair growth efficacy of beta-sitosterol for treating alopecia.

This study found that minoxidil and ranolazine, individually and in combination, reduced cellular invasiveness in hypoxic triple-negative breast cancer cell lines, suggesting potential anti-metastatic effects at clinically relevant doses.

In a randomized controlled trial, King et al. found that oral baricitinib at doses of 2 mg and 4 mg significantly improved hair regrowth in adults with alopecia areata compared to placebo, supporting its efficacy and safety for those with substantial scalp hair loss.

In this study, the use of "ProFecund Ino," a myo-inositol-based treatment for women with PCOS, was associated with a 38% pregnancy rate, and when combined with reproductive techniques, it significantly increased pregnancy chances.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This study found that baricitinib is effective for treating severe alopecia areata, with significant hair regrowth observed by the third month of therapy and continued improvement by month 12, while adverse events were mainly mild.

This review discusses the potential of using sustained release systems to increase the effectiveness and reduce side effects of 17-alpha-estradiol in alopecia treatment and reports no clinical results.

This review discusses the pathophysiology of polycystic ovary syndrome and its non-pharmacological and pharmacological treatment options, but reports no new clinical results.

In this study on C3H/HeJ-engrafted mice, a single injection of BMD-1141 significantly increased anagen hair follicle counts and enhanced hair regrowth compared to daily high-dose ruxolitinib, suggesting it stimulates hair growth by influencing the hair cycle rather than altering immune response.

This study found that lower serum vaspin levels (below 3.74ng/mL) may predict successful ovulation induction with clomiphene citrate in anovulatory women with PCOS, indicating potential resistance when levels are higher.

This article reviews the diverse clinical applications of oral contraceptives beyond birth control, suggesting their effectiveness in treating various female health disorders and conditions.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

In this study, 33 overweight women with normal hormone levels but showing PCOS symptoms experienced substantial reductions in acne lesions and improvements in hirsutism and menstrual irregularities after 8 weeks of Tracnil™ treatment, with minimal adverse reactions reported.

In this study, a single subcutaneous dose of PTH-CBD showed similar hair regrowth to daily oral ruxolitinib in mice with alopecia, possibly through increased beta-catenin and anagen transition stimulation.

Early sunburn treatment with certain inhibitors may reduce skin cancer risk.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This study observed that Icariside II, an extract from Epimedium brevicornu Maxim, can inhibit the growth of gastric cancer in cell lines and mouse models by promoting apoptosis and suppressing the Wnt/β-catenin signaling pathway, with minimal toxicity to normal gastric cells.

This analysis reports no significant differences between spironolactone and metformin for managing PCOS, noting spironolactone remains a potential off-label option for patients unable to use hormonal contraceptives, but larger studies are necessary to confirm its efficacy.

In this study, voglibose, commonly used for diabetes management, was found to reduce melanin synthesis and inhibit melanogenic signaling pathways in B16F10 melanoma cells, suggesting it could be repurposed for treating hyperpigmentation disorders with confirmed topical safety in human tests.

This study found that among eleven tested polymethoxyflavones, 5-hydroxy-7,4′-dimethoxyflavone was the strongest steroid 5α-reductase inhibitor and suggests potential use for benign prostatic hyperplasia treatment.

This study documented a case where the medication baricitinib effectively promoted hair regrowth in a woman with alopecia areata but also led to an unexpected side effect of hypertrichosis, suggesting a need to further explore the JAK/STAT pathway's role in hair growth dynamics.

This review discusses contraceptive options for adolescent girls, highlighting potential recommendations and contraindications, and reports no new clinical findings.

This study found that a once-daily capsule of minoxidil and spironolactone may safely reduce hair loss severity in women with female pattern hair loss.

In a real-world study, baricitinib was effective for scalp, eyebrow, and eyelash regrowth in patients with alopecia areata, showing clinically meaningful improvements as early as 3 months and increasing up to 12 months; satisfaction and perceived improvement were also high among participants.

This report describes a case where a young woman developed Kerion Celsi, a fungal skin infection, potentially linked to the use of a tretinoin, minoxidil, and betamethasone valerate lotion.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

In this report, oral baricitinib improved both alopecia areata and immune thrombocytopenia in a 56-year-old patient, suggesting a potential dual benefit for these conditions, although regular platelet monitoring and hematology consultation are recommended.

This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.

This systematic review evaluates the effectiveness and safety of various treatments for polycystic ovary syndrome including finasteride, flutamide, and metformin, but does not provide specific new results.

In this study, treatment with flutamide combined with a low-dose oral contraceptive significantly improved hirsutism in women with polycystic ovarian disease who did not respond to oral contraceptive treatment alone.